Skip to content
2000
image of Brusatol Regulates Ferroptosis of Ovarian Cancer Through the Nrf2/HO-1/NQO1 and AKT/mTOR Double Signaling Pathways
file format pdf download PDF

Abstract

Introduction

Ovarian cancer (OC) is a common malignant tumor of the female reproductive system and is usually found at an advanced stage. However, the treatment of OC with conventional the efficacy of surgery and chemotherapy is limited. Brusatol (BRU) is a unique nuclear factor erythroid 2-related factor 2 (Nrf2) pathway inhibitor with significant anti-cancer effects. At the same time, the Nrf2 system also plays a vital role in ferroptosis, which can be used as a new way to treat tumors. This study investigated the mechanism of action of BRU as a novel ferroptosis inducer to inhibit OC cells.

Methods

Using bioinformatics to screen for key targets and pathways that act on OC in BRU, and then the effects of BRU on OC cells were examined by cell viability assay, clone formation assay, wound healing assay, and apoptosis assay. The intracellular levels of ROS (Reactive Oxygen Species), Fe2+, glutathione (GSH), and malondialdehyde (MDA) were also quantified. Western blotting analysis was then performed to verify ferroptosis marker proteins and pathways. In addition, the combination of Ferrostatin-1 (Fer-1) and BRU was further tested for ferroptosis-related markers.

Results

By obtaining BRU and OC targets, 171 potential BRU-OC action targets were screened to the core target NQO1. KEGG enrichment analysis showed that the anticancer effects of IBC were mediated through multiple pathways, including the PI3K-AKT and Ras signaling pathways. results showed that IBC inhibited the proliferation, invasion, and migration of OC cells and induced ferroptosis in OC cells.

Discussion

We demonstrated that BRU increased intracellular ROS, Fe2+, and MDA levels. It also significantly reduced intracellular GSH level and the expression of two marker proteins for ferroptosis, GPX4 and SLC7A11. Meanwhile, BRU could inhibit the Nrf2/HO-1/NQO1 and AKT/mTOR dual signaling pathways in OC cells. Furthermore, the combination of Ferrostatin-1 (Fer-1) and BRU reversed BRU-induced ferroptosis in OC cells.

Conclusion

In this study, we demonstrated for the first time through bioinformatics, molecular docking technology, and experimental validation that BRU acts as a novel inducer of ferroptosis in ovarian cancer cells by targeting the Nrf2/HO-1/NQO1 and AKT/mTOR dual signaling pathways, and may have great potential in the treatment of ovarian cancer cells.

© 2025 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128383328250808123933
2025-08-19
2025-11-02

  • From This Site

    /content/journals/cpd/10.2174/0113816128383328250808123933
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cpd/10.2174/0113816128383328250808123933/BMS-CPD-2025-16.html?itemId=/content/journals/cpd/10.2174/0113816128383328250808123933&mimeType=html&fmt=ahah

References

  1. Meyer L.A. He W. Sun C.C. Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness. Gynecol. Oncol. 2018 150 3 451 459 10.1016/j.ygyno.2018.06.020 29961559
    [Google Scholar]
  2. Webb P.M. Jordan S.J. Epidemiology of epithelial ovarian cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 2017 41 3 14 10.1016/j.bpobgyn.2016.08.006 27743768
    [Google Scholar]
  3. Lheureux S. Gourley C. Vergote I. Oza A.M. Epithelial ovarian cancer. Lancet 2019 393 10177 1240 1253 10.1016/S0140‑6736(18)32552‑2 30910306
    [Google Scholar]
  4. Jin Z. Chenghao Y. Cheng P. Anticancer effect of tanshinones on female breast cancer and gynecological cancer. Front. Pharmacol. 2022 12 824531 10.3389/fphar.2021.824531 35145409
    [Google Scholar]
  5. Chilimoniuk Z. Rocka A. Stefaniak M. Molecular methods for increasing the effectiveness of ovarian cancer treatment: A systematic review. Future Oncol. 2022 18 13 1627 1650 10.2217/fon‑2021‑0565 35129396
    [Google Scholar]
  6. HemaIswarya S Doble M. Potential synergism of natural products in the treatment of cancer. Phytother. Res. 2006 20 4 239 249 10.1002/ptr.1841 16557604
    [Google Scholar]
  7. Wang L. Wang Z. Ni Y. Elucidating the mechanism of action of Isobavachalcone induced autophagy and apoptosis in non-small cell lung cancer by network pharmacology and experimental validation methods. Gene 2024 918 148474 10.1016/j.gene.2024.148474 38670393
    [Google Scholar]
  8. Chen X. Yin T. Zhang B. Inhibitory effects of brusatol delivered using glycosaminoglycan placental chondroitin sulfate A modified nanoparticles on the proliferation, migration and invasion of cancer cells. Int. J. Mol. Med. 2020 46 2 817 827 10.3892/ijmm.2020.4627 32626948
    [Google Scholar]
  9. Ye R. Dai N. He Q. Comprehensive anti-tumor effect of Brusatol through inhibition of cell viability and promotion of apoptosis caused by autophagy via the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Biomed. Pharmacother. 2018 105 962 973 10.1016/j.biopha.2018.06.065 30021391
    [Google Scholar]
  10. Evans J.P. Winiarski B.K. Sutton P.A. The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer. Oncotarget 2018 9 43 27104 27116 10.18632/oncotarget.25497 29930754
    [Google Scholar]
  11. Oh E.T. Kim C.W. Kim H.G. Lee J.S. Park H.J. Brusatol-mediated inhibition of c-Myc increases HIF-1α degradation and causes cell death in colorectal cancer under hypoxia. Theranostics 2017 7 14 3415 3431 10.7150/thno.20861 28912885
    [Google Scholar]
  12. Xiang Y. Ye W. Huang C. Brusatol enhances the chemotherapy efficacy of gemcitabine in pancreatic cancer via the Nrf2 signalling pathway. Oxid. Med. Cell. Longev. 2018 2018 1 2360427 10.1155/2018/2360427 29849873
    [Google Scholar]
  13. Lu Z. Lai Z.Q. Leung A.W.N. Leung P.S. Li Z.S. Lin Z.X. Exploring brusatol as a new anti-pancreatic cancer adjuvant: Biological evaluation and mechanistic studies. Oncotarget 2017 8 49 84974 84985 10.18632/oncotarget.17761 29156697
    [Google Scholar]
  14. Lee J.H. Rangappa S. Mohan C.D. Brusatol, a Nrf2 inhibitor targets STAT3 signaling cascade in head and neck squamous cell carcinoma. Biomolecules 2019 9 10 550 10.3390/biom9100550 31575007
    [Google Scholar]
  15. Liu Y. Lu Y. Celiku O. Targeting IDH1-mutated malignancies with NRF2 blockade. J. Natl. Cancer Inst. 2019 111 10 1033 1041 10.1093/jnci/djy230 30759236
    [Google Scholar]
  16. Liu X. Xu H. Zhang Y. Wang P. Gao W. Brusatol inhibits amyloid‐β‐induced neurotoxicity in U‐251 cells via regulating the Nrf2/HO‐1 pathway. J. Cell. Biochem. 2019 120 6 10556 10563 10.1002/jcb.28341 30629288
    [Google Scholar]
  17. Cai S.J. Liu Y. Han S. Yang C. Brusatol, an NRF2 inhibitor for future cancer therapeutic. Cell Biosci. 2019 9 1 45 10.1186/s13578‑019‑0309‑8 31183074
    [Google Scholar]
  18. Sun X. Wang Q. Wang Y. Du L. Xu C. Liu Q. Brusatol enhances the radiosensitivity of A549 cells by promoting ROS production and enhancing DNA damage. Int. J. Mol. Sci. 2016 17 7 997 10.3390/ijms17070997 27347930
    [Google Scholar]
  19. Ren D. Villeneuve N.F. Jiang T. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc. Natl. Acad. Sci. USA 2011 108 4 1433 1438 10.1073/pnas.1014275108 21205897
    [Google Scholar]
  20. Dixon S.J. Stockwell B.R. The role of iron and reactive oxygen species in cell death. Nat. Chem. Biol. 2014 10 1 9 17 10.1038/nchembio.1416 24346035
    [Google Scholar]
  21. Dixon S.J. Lemberg K.M. Lamprecht M.R. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 2012 149 5 1060 1072 10.1016/j.cell.2012.03.042 22632970
    [Google Scholar]
  22. Dodson M. Castro-Portuguez R. Zhang D.D. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol. 2019 23 101107 10.1016/j.redox.2019.101107 30692038
    [Google Scholar]
  23. Zhang H. Yuan B. Huang H. Qu S. Yang S. Zeng Z. Gastrodin induced HO-1 and Nrf2 up-regulation to alleviate H2O2-induced oxidative stress in mouse liver sinusoidal endothelial cells through p38 MAPK phosphorylation. Braz. J. Med. Biol. Res. 2018 51 10 7439 10.1590/1414‑431x20187439 30156611
    [Google Scholar]
  24. Fan Z. Wirth A-K. Chen D. Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis. Oncogenesis 2017 6 8 371 10.1038/oncsis.2017.65 28805788
    [Google Scholar]
  25. Jing T. Guo Y. Wei Y. Carboxymethylated pachyman induces ferroptosis in ovarian cancer by suppressing NRF1/HO 1 signaling. Oncol. Lett. 2022 23 5 161 10.3892/ol.2022.13281 35399331
    [Google Scholar]
  26. Li S. Zhang Y. Zhang J. Neferine exerts ferroptosis-inducing effect and antitumor effect on thyroid cancer through Nrf2/HO-1/] NQO1 inhibition. J. Oncol. 2022 2022 1 16 10.1155/2022/7933775 35794985
    [Google Scholar]
  27. Zhu W. Li Y. Zhao J. Wang Y. Li Y. Wang Y. The mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking. Ann. Med. 2022 54 1 541 552 10.1080/07853890.2022.2034931 35132912
    [Google Scholar]
  28. Sellers T.A. Peres L.C. Hathaway C.A. Tworoger S.S. Prevention of epithelial ovarian cancer. Cold Spring Harb. Perspect. Med. 2023 13 8 a038216 10.1101/cshperspect.a038216 37137500
    [Google Scholar]
  29. Smith M.A. Seibel N.L. Altekruse S.F. Outcomes for children and adolescents with cancer: Challenges for the twenty-first century. J. Clin. Oncol. 2010 28 15 2625 2634 10.1200/JCO.2009.27.0421 20404250
    [Google Scholar]
  30. Sutton G.P. Stehman F.B. Einhorn L.H. Roth L.M. Blessing J.A. Ehrlich C.E. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J. Clin. Oncol. 1989 7 2 223 229 10.1200/JCO.1989.7.2.223 2915238
    [Google Scholar]
  31. Yu X. He Z. Wang Z. Brusatol hinders the progression of bladder cancer by Chac1/Nrf2/SLC7A11 pathway. Exp. Cell Res. 2024 438 2 114053 10.1016/j.yexcr.2024.114053 38663476
    [Google Scholar]
  32. Yu X. Shang X. Huang X. Yao G. Song S. Brusatol: A potential anti-tumor quassinoid from Brucea javanica. Chin. Herb. Med. 2020 12 4 359 366 10.1016/j.chmed.2020.05.007 36120179
    [Google Scholar]
  33. Hu M. Sun D. Yu J. Brusatol sensitizes endometrial hyperplasia and cancer to progestin by suppressing NRF2-TET1-AKR1C1-mediated progestin metabolism. Lab. Invest. 2022 102 12 1335 1345 10.1038/s41374‑022‑00816‑5 36038734
    [Google Scholar]
  34. Hsin K.Y. Ghosh S. Kitano H. Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology. PLoS One 2013 8 12 83922 10.1371/journal.pone.0083922 24391846
    [Google Scholar]
  35. Qiu Y. Cao Y. Cao W. Jia Y. Lu N. The application of ferroptosis in diseases. Pharmacol. Res. 2020 159 104919 10.1016/j.phrs.2020.104919 32464324
    [Google Scholar]
  36. Conrad M. Sato H. The oxidative stress-inducible cystine/] glutamate antiporter, system x c −: Cystine supplier and beyond. Amino Acids 2012 42 1 231 246 10.1007/s00726‑011‑0867‑5 21409388
    [Google Scholar]
  37. Sato H. Tamba M. Ishii T. Bannai S. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J. Biol. Chem. 1999 274 17 11455 11458 10.1074/jbc.274.17.11455 10206947
    [Google Scholar]
  38. Stockwell B.R. Friedmann Angeli J.P. Bayir H. Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell 2017 171 2 273 285 10.1016/j.cell.2017.09.021 28985560
    [Google Scholar]
/content/journals/cpd/10.2174/0113816128383328250808123933
Loading
Brusatol Regulates Ferroptosis of Ovarian Cancer Through the Nrf2/HO-1/NQO1 and AKT/mTOR Double Signaling Pathways
Bentham Science Publishers ; https://doi.org/10.2174/0113816128383328250808123933
/content/journals/cpd/10.2174/0113816128383328250808123933
/content/journals/cpd/10.2174/0113816128383328250808123933
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: Nrf2/HO-1/NQO1 pathway ; AKT/mTOR pathway ; Brusatol ; OC targets ; Ferroptosis ; ovarian cancer

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test